Mednet Logo
HomeGynecologic OncologyQuestion

Does the path length of vaginal cuff cylinder brachytherapy treatment as adjuvant therapy for endometrial cancer vary based on histology (serous, etc)?

3
4 Answers
Mednet Member
Mednet Member
Radiation Oncology · Abramson Cancer Center, University of Pennsylvania

There was some thought that treatment of high risk histologies, positive LVI, or high Grade required a longer vaginal length be treated. Including 2/3 or full length. That is largely unsupported by high-quality data and would increase distal vagina toxicity in this population.

Our clinic treats uppe...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

I don’t change the length of vaginal treatment for adjuvant brachytherapy alone based on histology.

The only thing I do differently is in high risk disease who need EBRT, I treat the larger length of vagina with EBRT followed by brachy boost to upper 3 cm only.

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Vanderbilt-Ingram Cancer Center

Anecdotally, my institution has seen a few mid vaginal recurrences in high-risk histology (serous/carcinosarcoma/clear cell) patients treated to a 'standard' distance of 3 cm of proximal vagina, which became very challenging salvage situations.

Thus, I do change my treatment length based on histolog...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Sunnybrook Health Sciences Centre

I also agree with what has been discussed above by @Dr. First Last and @Dr. First Last. We don't change the path length based on histology as there is limited data to support this.

Register or Sign In to see full answer

Does the path length of vaginal cuff cylinder brachytherapy treatment as adjuvant therapy for endometrial cancer vary based on histology (serous, etc)? | Mednet